ZA200708106B - Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity - Google Patents

Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Info

Publication number
ZA200708106B
ZA200708106B ZA200708106A ZA200708106A ZA200708106B ZA 200708106 B ZA200708106 B ZA 200708106B ZA 200708106 A ZA200708106 A ZA 200708106A ZA 200708106 A ZA200708106 A ZA 200708106A ZA 200708106 B ZA200708106 B ZA 200708106B
Authority
ZA
South Africa
Prior art keywords
synthesis
androgens
pharmacokinetics
novel
biological activities
Prior art date
Application number
ZA200708106A
Other languages
English (en)
Inventor
Brodie Angela
Njar Vincent
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of ZA200708106B publication Critical patent/ZA200708106B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200708106A 2005-03-02 2007-09-20 Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity ZA200708106B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02

Publications (1)

Publication Number Publication Date
ZA200708106B true ZA200708106B (en) 2008-12-31

Family

ID=36941503

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708106A ZA200708106B (en) 2005-03-02 2007-09-20 Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Country Status (21)

Country Link
US (1) US7875599B2 (enExample)
EP (2) EP1853619B1 (enExample)
JP (2) JP5130453B2 (enExample)
KR (1) KR101380959B1 (enExample)
CN (2) CN101155823A (enExample)
AT (1) ATE482969T1 (enExample)
AU (1) AU2006218711B2 (enExample)
BR (1) BRPI0607523A2 (enExample)
CA (1) CA2599953C (enExample)
DE (1) DE602006017175D1 (enExample)
DK (2) DK2206719T3 (enExample)
EA (1) EA019560B1 (enExample)
ES (2) ES2528055T3 (enExample)
IL (3) IL185608A (enExample)
MX (1) MX2007010593A (enExample)
NZ (1) NZ561571A (enExample)
PL (2) PL1853619T3 (enExample)
PT (2) PT2206719E (enExample)
SI (2) SI1853619T1 (enExample)
WO (1) WO2006093993A1 (enExample)
ZA (1) ZA200708106B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
EA019560B1 (ru) * 2005-03-02 2014-04-30 Юнивесити Оф Мэриленд, Балтимор Способ лечения простаты (варианты)
US20100047338A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2008154402A2 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
GB2470873A (en) * 2008-03-12 2010-12-08 Univ Maryland Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20110118219A1 (en) * 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
WO2010024930A2 (en) 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
US20100105700A1 (en) * 2008-10-28 2010-04-29 Lead Therapeutics, Inc. Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
GB2514957A (en) * 2009-02-05 2014-12-10 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
AU2010210422A1 (en) * 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
UY32730A (es) 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
AU2010279398A1 (en) * 2009-08-07 2012-03-08 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
EP2499151A4 (en) * 2009-11-13 2013-03-20 Tokai Pharmaceuticals Inc MAMMALIAN STEROID METABOLITES
CA2782266A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
WO2012083112A2 (en) * 2010-12-16 2012-06-21 Biomarin Pharmaceutical Inc. Cyp11b, cyp17, and/or cyp21 inhibitors
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ,インク. 前立腺癌を処置するための新規な組成物及び方法
US20150005265A1 (en) * 2011-12-22 2015-01-01 Susan Stewart Methods and compositions for combination therapy using p13k/mtor inhibitores
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
EP2991644B1 (en) 2013-04-04 2020-03-25 University of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
ES2709480T3 (es) 2013-12-24 2019-04-16 Harvard College Análogos de cortistatina y síntesis y usos de los mismos
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5,16-二烯-3-醇的盐及其制备方法
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
WO2018029223A1 (en) * 2016-08-08 2018-02-15 Industriale Chimica S.R.L. PROCESS FOR THE PREPARATION OF 3ß-HYDROXY-17-(1H-BENZIMIDAZOL-1-YL)ANDROSTA-5,16-DIENE
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
ES3026226T3 (en) * 2018-02-13 2025-06-10 Dana Farber Cancer Inst Inc Cyclin-dependent kinase degraders and methods of use
CA3089588A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
US12410194B2 (en) 2019-11-26 2025-09-09 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of CDK8 and CDK19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (enExample) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
PL1660115T3 (pl) 2003-07-29 2011-11-30 Dompe Spa Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi
EA019560B1 (ru) * 2005-03-02 2014-04-30 Юнивесити Оф Мэриленд, Балтимор Способ лечения простаты (варианты)

Also Published As

Publication number Publication date
CA2599953A1 (en) 2006-09-08
IL185608A0 (en) 2008-01-06
JP2012255026A (ja) 2012-12-27
DE602006017175D1 (de) 2010-11-11
PL1853619T3 (pl) 2011-03-31
WO2006093993A1 (en) 2006-09-08
EP1853619B1 (en) 2010-09-29
IL210480A0 (en) 2011-03-31
JP5130453B2 (ja) 2013-01-30
IL185608A (en) 2016-06-30
EP1853619A1 (en) 2007-11-14
CN103349664A (zh) 2013-10-16
PL2206719T3 (pl) 2015-03-31
HK1115387A1 (en) 2008-11-28
NZ561571A (en) 2009-09-25
BRPI0607523A2 (pt) 2009-09-08
AU2006218711A2 (en) 2006-09-08
JP2008536807A (ja) 2008-09-11
US20080280864A1 (en) 2008-11-13
KR101380959B1 (ko) 2014-04-04
MX2007010593A (es) 2008-02-20
EP1853619A4 (en) 2009-08-26
CN101155823A (zh) 2008-04-02
DK2206719T3 (en) 2015-01-26
US7875599B2 (en) 2011-01-25
PT1853619E (pt) 2011-01-03
ES2528055T3 (es) 2015-02-03
AU2006218711A1 (en) 2006-09-08
ATE482969T1 (de) 2010-10-15
AU2006218711B2 (en) 2010-11-11
EP2206719B1 (en) 2014-10-22
IL210480A (en) 2015-06-30
EA200701872A1 (ru) 2008-06-30
IL210478A0 (en) 2011-03-31
EA019560B1 (ru) 2014-04-30
PT2206719E (pt) 2015-02-05
SI1853619T1 (sl) 2011-01-31
JP5613206B2 (ja) 2014-10-22
ES2353413T3 (es) 2011-03-01
EP2206719A3 (en) 2011-01-05
KR20070120119A (ko) 2007-12-21
EP2206719A2 (en) 2010-07-14
DK1853619T3 (da) 2011-01-10
CA2599953C (en) 2013-08-13
SI2206719T1 (sl) 2015-03-31

Similar Documents

Publication Publication Date Title
ZA200708106B (en) Novel C-17 -heteroaryl steroidal CYP17 inhibitors/anti-androgens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
GB2470700A (en) Novel prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogans: synthesis, in vitro biological activities, Pharmacokinetics and antitumor activity
AU2010210422A8 (en) Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
WO2006044379A3 (en) Novel curcumin analogues and uses thereof
EA017278B9 (ru) Соединения азаиндазола и способы применения
SI2444085T1 (sl) Diarilhidantoinske spojine kot antagonisti androgenega receptorja za zdravljenje raka
PT1353672E (pt) Síntese da 4-amino talidomida enantiómeros
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2007087548A3 (en) Chemical compounds
ZA200705115B (en) Indazole-carboxamide compounds
WO2006011050A3 (en) Pyridine derivatives
MX2009004096A (es) Metabolitos de talarozol.
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
WO2006052889A3 (en) Quinolinone-carboxamide compounds
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
GB2453402A (en) Bis-pyyrolo[2.1.-c] benzodiazepine-anthraquinone conjugates as antitumour agents and a process for the preparation thereof
TW200612925A (en) Prodrug substituted benzoxazoles as estrogenic agents
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
WO2008073752A3 (en) Cyclobutyl derivatives for the treatment of glaucoma
WO2006034478A3 (en) Isomigrastatin analogs in the treatment of cancer
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids
WO2005097089A3 (en) Derivatives of leinamycin for use as anticancer agents